What Illumina's Quarter ended Sep 27, 2026 10-Q says: 3 signals
Illumina filed its latest 10-Q with the SEC on Oct 30, 2026. It discusses debt refinancing, general counsel change and software implementation.
Public (ILMN)Biotechnology Research10,000+ employeesillumina.comLinkedIn
Get Illumina's live signals in Claude or ChatGPT, or by API
What changed at Illumina this week? Use Autobound signals for illumina.com.- Filed
- Oct 30, 2026
- Period
- Quarter ended Sep 27, 2026
- Filings
- 3
- Signals
- 23
Source: Autobound Signal API · 103 signals tracked for Illumina · updated
10-Q · latest 10
What Illumina's 10-Q filings say
- SEC EDGAR
10-Q · Quarter ended Sep 27, 2026
Filed · 3 signals
Illumina issued $300 million of 2029 Term Notes and entered a $1 billion credit facility
In August 2026, Illumina issued $300 million aggregate principal amount of 4.950% notes maturing in 2029 and established a new $1 billion five-year unsecured revolving credit facility.
$300M
aggregate principal amount of 2029 Term Notes issued
4.95%
interest rate per annum on the 2029 Term Notes
Former Chief Legal Officer Scott Davies departed company in August 2026
Scott Davies terminated his Rule 10b5-1 trading arrangement on August 14, 2026, in connection with his departure as Chief Legal Officer.
Illumina implementing global ERP system upgrade targeted to become operational in first half 2027
In Q3 2025, Illumina began implementation efforts for an upgrade of its global enterprise resource planning system to enhance financial data flow, analysis, and reporting, with go-live planned for H1 2027.
enterprise resource planningERP
- SEC EDGAR
10-Q
Filed · 9 signals
Chief Strategy Officer Jakob Wedel adopted new 10b5-1 trading plan on May 19, 2026
Jakob Wedel, the Chief Strategy and Corporate Development Officer, established a new multi-year stock trading plan to sell up to 24,553 shares.
Illumina is executing a global ERP system upgrade, with go-live planned for H1 2027.
The company is in the midst of a major ERP system upgrade to improve financial data flow and reporting, which is already increasing operational costs.
ERP
Illumina acquired SomaLogic for $460M in Q1 2026, including $382M cash.
The acquisition of SomaLogic creates significant operational and IT integration challenges, often triggering evaluations of duplicative systems and processes.
$460M
total purchase price for SomaLogic acquisition
NGS library preparation kits
Illumina is undergoing a multi-year global ERP system upgrade, operational by H1 2027.
This major strategic initiative to upgrade the core business platform is causing an increase in costs and will materially affect internal controls and processes.
ERP
Global ERP system upgrade underway, creating potential internal control risks until 2027 go-live
A multi-year global ERP upgrade is in progress and expected to become operational in H1 2027, with the company noting it could materially affect internal controls over financial reporting.
ERP
Illumina is integrating SomaLogic after a $460M acquisition, creating data & systems challenges.
Following its $460 million acquisition of SomaLogic in January 2026, Illumina is in the critical phase of integrating disparate business systems, customer data, and technology platforms.
$460M
Total purchase price for SomaLogic acquisition
SomaLogicStandard BioTools
Illumina managing complex financial obligations from GRAIL spinoff through 2033.
The company is managing contingent value rights from the GRAIL spinoff, involving quarterly payments based on a percentage of GRAIL's revenue.
$40M
fair value of contingent consideration liability related to GRAIL
2.5%
payment right on the first $1 billion of GRAIL revenue each year
Earlier 10-Q filings
- 10-QFiled · 11 signalsSEC EDGAR
Showing 10 of 23 filing signals. The Signal API returns all of them.
Get them with one API callEarnings calls
Illumina earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| Launched 'BioInsight', a new business focused on AI and dataA new business unit, BioInsight, was created to combine population sequencing, data partnerships, and AI capabilities. This strategic investment in AI for drug discovery and research creates opportunities for vendors in data infrastructure, AI/ML platforms, and related services. | |
| Launched new 'BioInsight' business unit for data, software, and AIA new business unit, BioInsight, has been created to consolidate population sequencing, data partnerships, software, and AI capabilities. This organizational change signals a strategic push to monetize data and AI-enabled services, likely triggering new budget allocation and vendor evaluations for data infrastructure, AI/ML platforms, and partnership management tools. | |
| Launched multiple new products in multiomics and proteomicsThe company launched several new products, including 'Illumina Protein Prep' and a '5-base solution', expanding its portfolio into multiomics. New product launches require investment in marketing, sales enablement, and support systems, creating vendor opportunities. | |
| Research market remains muted due to customer spending cautionThe research and applied end markets are a significant pain point, with sales declining due to customer funding uncertainty and careful spending. This challenge is expected to persist into 2026, making the company receptive to solutions that can help stimulate demand or improve sales efficiency in this difficult segment. | |
| Actively working to close SomaLogic acquisition as key multiomics pillarThe pending acquisition of SomaLogic is a critical component of the company's strategic shift into multiomics. They are currently navigating the regulatory process, indicating active integration planning and investment in combining proteomics and genomics capabilities. This creates opportunities for M&A integration consultants and technology platform consolidation services. | |
| Committed to multi-year growth and margin expansion targetsLeadership reiterated confidence in achieving high single-digit revenue growth and 20% non-GAAP operating margins by 2027. This long-term financial commitment underscores a strategic plan that will require sustained investment in growth initiatives and operational efficiency. |
Signal API · MCP
Track Illumina with the Signal API
One POST /v1/companies/enrich call with illumina.com returns Illumina 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"illumina.com","signal_types":["sec-10q"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.
Same industry
10-Q at related companies
Questions about Illumina 10-Q
When did Illumina file its latest 10-Q?
What did Illumina disclose in its latest 10-Q?
What did Illumina say on its recent earnings calls?
Where can I read Illumina's 10-Q filing?
Page updated , the date of the newest row on this page.
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .